Gilead Sciences | Passifs Courants



Current Liabilities Changement Date
AbbVie USD 36.4B 2.35B 2025-03
Agios Pharmaceuticals USD 70.41M 18.04M 2025-06
ALKERMES USD 505.96M 62.23M 2025-06
Alnylam Pharmaceuticals USD 1.3B 225.22M 2025-06
Amgen USD 20.48B 2.53B 2025-06
Biogen USD 3.18B 2.11B 2025-06
BioMarin Pharmaceutical USD 684.25M 56.03M 2025-06
Bristol-Myers Squibb USD 27.53B 3.46B 2025-06
Eli Lilly USD 39.02B 8.95B 2025-06
Gilead Sciences USD 11.19B 1.15B 2025-06
GlaxoSmithKline GBP 20.38B 453M 2025-06
Glaxosmithkline GBP 21.7B 238M 2024-12
Incyte USD 1.28B 608.18M 2025-06
J&J USD 56.9B 6.58B 2025-03
Merck USD 26.04B 863M 2025-06
Moderna USD 1.57B 32M 2025-06
Neurocrine Biosciences USD 546.3M 23.4M 2025-06
Novartis USD 31.71B 95M 2025-06
Pfizer USD 37.73B 1.27B 2025-06
PTC Therapeutics USD 627.81M 32.42M 2025-06
Regeneron Pharmaceuticals USD 3.67B 100.4M 2025-06
Sanofi 29.06B 3.16B 2025-06
Sarepta Therapeutics USD 919.95M 314.36M 2025-06
United Therapeutics USD 527.1M 194.4M 2025-06
Vertex Pharmaceuticals USD 4.14B 355.2M 2025-06


Gilead Sciences Passifs Courants - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Aug 2025.